Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) shares shot up 3.8% during trading on Wednesday . The company traded as high as $2.97 and last traded at $2.97. 25,752 shares changed hands during trading, a decline of 42% from the average session volume of 44,128 shares. The stock had previously closed at $2.86.
Phio Pharmaceuticals Price Performance
The company has a market capitalization of $3.13 million, a price-to-earnings ratio of -0.27 and a beta of 1.49. The business has a fifty day moving average price of $2.88 and a 200 day moving average price of $3.98.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Further Reading
- Five stocks we like better than Phio Pharmaceuticals
- Health Care Stocks Explained: Why You Might Want to Invest
- Tesla Poised to Hit Record Highs This Holiday Season
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- The Salesforce Rally is Just Getting Started: Here’s Why
- Investing in Construction Stocks
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
